Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Durvalumab plus bevacizumab plus TACE has the potential to set a new standard of care. With additional follow-up of the EMERALD-1 study, future analyses, including the final overall survival data and patient-reported outcomes, will help to further characterise the potential clinical benefits of durvalumab plus bevacizumab plus TACE in hepatocellular carcinoma amenable to embolisation.

Read the full article here

Source: www.thelancet.com

Categories: General HCPs, General Medicine News

Tweets with this article

The Lancet

Immunotherapy in addition to current treatment significantly delays liver cancer progression, show two phase 3 clinical trials. EMERALD-1 👉 https://t.co/GNllEQYPv6 LEAP-012 👉 https://t.co/hEoTB5pkZS https://t.co/HqaoBtAKGn

America’s Most Common Drug Problem? Unhealthy Alcohol Use

Alcohol is the leading driver of substance use-related fatalities in America: Each year, frequent or excessive drinking causes approximately 178,000 deaths. Excessive alcohol use is…

Pew Health January 10, 2025

TikTok says it plans to shut down site unless Supreme Court strikes down law forcing it to sell

Court to hear arguments Friday on law forcing TikTok sale by Chinese parent company that takes effect in Jan. 19.

Evan Kirstel the $B2B Techfluencer January 10, 2025

Hypoglossal Nerve Stimulation and Innovations in the Management of Obstructive Sleep Apnea (podcast)

In a recent episode of Cleveland Clinic’s Head and Neck Innovations podcast, Alan Kominsky, MD delves into the evolution of surgical sleep therapy.

Cleveland Clinic MD January 10, 2025

Exchange subsidies not doomed under GOP rule

Republicans have fought “Obamacare” for 15 years, but millions of their own constituents have health coverage because of it.

Modern Healthcare January 10, 2025

Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes

ApoE2 and ApoE Christchurch variants are defective in LDLR binding, thus reducing the uptake of ApoE and associated lipid cargoes. LDLR-mediated internalization and endolysosomal delivery…

Cell January 10, 2025

Innovaccer Rakes In $275M, Kicking Off What Will Likely Be Another Hot Year for AI Funding – MedCity News

Healthcare AI company Innovaccer closed a $275 million Series F funding round, bringing its fundraising total to date to $675 million. The company has plans…

MedCity News January 10, 2025

Host metabolism balances microbial regulation of bile acid signalling

Nature – A family of host-derived bile acid–methylcysteamine conjugates functions as FXR antagonists, forming part of a microbiota-dependent metabolic network that regulates FXR-dependent…

Medical Xpress January 10, 2025

Skin of Color Savvy: Itch in Skin of Color, with Andrew Alexis, MD, MPH, and Shawn Kwatra, MD

In the inaugural episode of Skin of Color Savvy, Andrew Alexis, MD, MPH, and Shawn Kwatra, MD, discuss diagnosis and management of itch in skin…

MD Mag January 10, 2025

Across U.S., physicians share top state advocacy priorities for 2025

As the AMA State Advocacy Summit gets underway, new survey data shows what will keep doctors and medical society staffers busy in statehouses this year.

AMA January 10, 2025

Ribosome customization and functional diversification among P-stalk proteins regulate late poxvirus protein synthesis

Khalatyan et al. show that poxvirus protein synthesis becomes dependent on 40S and 60S subunit proteins that are normally dispensable for most cellular mRNAs. RACK1 facilitates…

Cell Reports January 9, 2025

Related Articles